Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus.

Article Details

Citation
Copy to clipboard

Toniutto P, Fabris C, Bitetto D, Fornasiere E, Rapetti R, Pirisi M

Valopicitabine dihydrochloride:a specific polymerase inhibitor of hepatitis C virus.

Curr Opin Investig Drugs. 2007 Feb;8(2):150-8.

PubMed ID
17328231 [ View in PubMed
]
Abstract

Idenix Pharmaceuticals Inc and Novartis AG are codeveloping valopicitabine dihydrochloride, a once-daily oral nucleoside for the potential treatment of HCV infection. In January 2005, a phase IIa clinical trial comparing valopicitabine dihydrochloride with pegylated IFN in treatment-naive HCV patients was ongoing, in addition to a phase IIb trial in patients that had previously failed pegylated IFN and ribavirin combination therapy. In January 2006, an international phase III trial in treatment-refractory patients was planned for the first half of the year, with a phase III trial in treatment-naive individuals planned for the second half of the year.

DrugBank Data that Cites this Article

Drugs